Additionally, small cohort studies indicate that 30%-40% of infants hospitalized for bronchiolitis (severe bronchiolitis) will subsequently develop recurrent wheezing and childhood asthma. (Table S1 ) during the 2011-2014 winter seasons. Bronchiolitis was defined according to the American Academy of Pediatrics guidelines-acute respiratory illness with some combination of rhinitis, cough, tachypnea, wheezing, crackles, and retractions. 4 We excluded infants with previous enrollment during earlier bronchiolitis hospitalization, those who were transferred to a participating hospital >24 hours after the original hospitalization, those who were consented >24 hours after hospitalization, or those with known heart-lung disease, immunodeficiency, immunosuppression, or gestational age <32 weeks. All patients were treated at the discretion of the treating physician.
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Additionally, small cohort studies indicate that 30%-40% of infants hospitalized for bronchiolitis (severe bronchiolitis) will subsequently develop recurrent wheezing and childhood asthma. 1 However, it remains unclear which infants with severe bronchiolitis will develop these chronic respiratory outcomes. Within the limited literature, a single-center analysis of 81 infants with respiratory syncytial virus (RSV) bronchiolitis demonstrated that upregulated expression of CCL5 (previously known as RANTES; a b-chemokine chemoattractant for inflammatory cells such as eosinophils) in nasal epithelium was associated with higher risk of developing childhood asthma. 2 However, despite the heterogeneity of bronchiolitis and subsequent risks of adverse respiratory outcomes, 1 we are not aware of another study that has investigated the role of airway CCL5 in other important populations (eg, infants with rhinovirus bronchiolitis). In the current study, we examined the relationship between nasopharyngeal CCL5 levels and risks of developing recurrent wheezing, according to virus etiology, in a prospective cohort of infants with severe bronchiolitis.
Details of the study design, setting, participants, data collection, and analysis may be found in the Online Repository (Supplemental Methods). Briefly, this prospective cohort study, the 35th
Multicenter Airway Research Collaboration (MARC-35) 3 enrolled infants (age <12 months) at an initial episode of severe bronchiolitis at 17 sites across 14 US states (Table S1 ) during the 2011-2014 winter seasons. Bronchiolitis was defined according to the American Academy of Pediatrics guidelines-acute respiratory illness with some combination of rhinitis, cough, tachypnea, wheezing, crackles, and retractions. 4 We excluded infants with previous enrollment during earlier bronchiolitis hospitalization, those who were transferred to a participating hospital >24 hours after the original hospitalization, those who were consented >24 hours after hospitalization, or those with known heart-lung disease, IgE sensitization at the enrollment) and accounted for patient clustering at the hospital level. To examine the robustness of the findings, we conducted a series of sensitivity analyses. First, to address potential dilutions of the specimens, we normalized the CCL5 level by using RNase P (host housekeeping gene) copy number, as we have previously described. 6 Second, we performed a subgroup analysis excluding patients who had a breathing problem before the index hospitalization. Lastly, we modeled the outcome as a binary outcome by fitting a generalized linear mixed model for each of the 4 virology strata.
Of 921 infants in the longitudinal cohort, the median age was 3.2 months (IQR, 1.6-5.9 months) and 60% were male. Additionally, 44% were non-Hispanic white, 23% non-Hispanic black, and 30% Hispanics. All had detectable CCL5 at the index hospitaliza- Unadjusted Cox proportional hazards model because of the relatively small sample size. Bold results are statistically significant. mL (IQR, 42.0-103.9 pg/mL). Overall, 32% developed recurrent wheezing by age 3 years. Between CCL5 strata, most patient characteristics did not differ, while infants with low CCL5 levels were younger and more likely to have RSV infection (both P < 0.05; Table S2 ). There was a significant interaction between CCL5 levels and virus category with regard to risk of recurrent wheezing (P interaction = .01), indicating that CCL5-outcome associations differ by virus. Indeed, among infants with solo RSV infection, compared to those with low CCL5 levels, the risk of recurrent wheezing was significantly higher in those with intermediate and high CCL5 levels (25%, 33%, and 33%, respectively) with corresponding adjusted HR of 1.57 (95% CI, 1.06-2.31; P = .02) and 1.56 (95% CI, 1.04-2.32; P = .03; Table 1 and Figure 1 ). In contrast, among the 3 other virus categories, CCL5 levels were not significantly associated with risks of recurrent wheezing (all P ≥ .15; Table 1 and Figure S1 ). This heterogeneity persisted across the sensitivity analyses with the use of normalized CCL5 levels, exclusion of patients with prior breathing problems, and use of generalized linear mixed models (Table 1 ) ( Figure S2 ). center study of 320 Chinese infants with RSV bronchiolitis also demonstrated that a polymorphism in the CCL5 gene is associated with higher serum CCL5 levels and subsequent risks of recurrent wheezing by age 3 years. 8 Our current multicenter study of 921 infants with severe bronchiolitis corroborates these earlier reports on RSV bronchiolitis, and extends them by demonstrating the lack of association in infants with other virus infections (eg, rhinovirus bronchiolitis).
Exploring the underlying mechanism of these findings is beyond the scope of the current analysis. However, the association in solo RSV infection may be causal-ie, severe RSV infection promotes exuberant CCL5-induced airway inflammation thereby contributing to recurrent wheezing. Alternatively, the expression of CCL5 during RSV infection is genetically determined, 8 and hence elevated levels may be simply a marker of infants who are predisposed to develop recurrent wheezing. Interestingly, the CCL5-recurrent wheezing association was not observed in the other virus groups. The lack of significant association was also found in the RSV-rhinovirus coinfection group, while it is difficult to speculate whether rhinovirus infection modifies RSV-CCL5-recurrent wheezing associations given the limited sample size.
Regardless, our findings lend additional support to the emerging concept that bronchiolitis is a heterogeneous condition with different pathobiological mechanisms and risks of adverse respiratory outcomes. 1 Our study has potential limitations, such as parental report of wheezing outcome and the absence of a "control" group. Additionally, our observations were based on nasopharyngeal CCL5 levels, while bronchiolitis also involves lower airways. However, the literature has shown significant correlations between upper and lower airway inflammatory mediators, including CCL5. 9 The use of upper airway specimens is also unavoidable as lower airway sampling is overly invasive in young infants. Next, the current analysis investigated the relationship of airway CCL5 with risks of recurrent wheezing rather than incident asthma. However, the presence of recurrent wheezing carries a 5.5-fold increased risk of developing asthma by age 6 years. 10 Finally, while the study cohort comprised a racially/ethnically diverse US sample, we must cautiously generalize our inferences beyond infants with severe bronchiolitis. Still, our data remain directly relevant for 130 000 hospitalized US infants each year, of which 30%-40% will develop asthma. 
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